
Revolution Medicines, Inc.: shareholders and insiders
Price
$159.43
November 19, 2026Market cap $34.5B
What Ploutos Investor adds for Revolution Medicines
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 20% since Nov 4, 2026, when the 10-Q these figures come from was filed ($199.70 then, $159.43 on Nov 19, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$159M
12 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $151M by 12 people
- 2025: no buys, sold $7.5M by 5 people
- 2026: no buys, sold $151M by 12 people
- Nov 16, 2026Stephen Michael KelseySenior Advisor to the Chief Executive OfficerKind10b5-1
- Nov 16, 2026Stephen Michael KelseySenior Advisor to the Chief Executive OfficerKind10b5-1
- Nov 16, 2026Stephen Michael KelseySenior Advisor to the Chief Executive OfficerKind10b5-1
- Nov 16, 2026Stephen Michael KelseySenior Advisor to the Chief Executive OfficerKind10b5-1
- Nov 16, 2026Stephen Michael KelseySenior Advisor to the Chief Executive OfficerKind10b5-1
- Nov 16, 2026Stephen Michael KelseySenior Advisor to the Chief Executive OfficerKind10b5-1
- Nov 16, 2026Stephen Michael KelseySenior Advisor to the Chief Executive OfficerKind10b5-1
- Nov 13, 2026Flavia BorelliniDirectorKind
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Jack AndersChief Financial OfficerKind10b5-1
- Nov 11, 2026Alexis BorisyDirectorKind
- Nov 9, 2026Anthony ManciniChief Global Commercialization OfficerKind10b5-1
- Nov 9, 2026Anthony ManciniChief Global Commercialization OfficerKind10b5-1
- Nov 9, 2026Anthony ManciniChief Global Commercialization OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | 10b5-1 | 27.2K | $18.56 | $504.1K | Form 4 |
| Nov 16, 2026 | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | 10b5-1 | 11.5K | $166.75 | $1.9M | Form 4 |
| Nov 16, 2026 | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | 10b5-1 | 3,627 | $167.66 | $608.1K | Form 4 |
| Nov 16, 2026 | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | 10b5-1 | 8,039 | $168.64 | $1.4M | Form 4 |
| Nov 16, 2026 | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | 10b5-1 | 3,052 | $169.46 | $517.2K | Form 4 |
| Nov 16, 2026 | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | 10b5-1 | 700 | $170.40 | $119.3K | Form 4 |
| Nov 16, 2026 | Stephen Michael KelseySenior Advisor to the Chief Executive Officer | 10b5-1 | 200 | $171.65 | $34.3K | Form 4 |
| Nov 13, 2026 | Flavia BorelliniDirector | 2,500 | $37.54 | $93.9K | Form 4 | |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 15.9K | $42.45 | $675.0K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 19.9K | $18.56 | $368.4K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 3,499 | $181.04 | $633.5K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 5,776 | $182.09 | $1.1M | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 2,700 | $182.87 | $493.8K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 1,900 | $184.02 | $349.6K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 800 | $185.04 | $148.0K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 400 | $186.41 | $74.6K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 600 | $187.34 | $112.4K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 200 | $189.17 | $37.8K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 500 | $190.99 | $95.5K | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 9,486 | $191.94 | $1.8M | Form 4 |
| Nov 11, 2026 | Jack AndersChief Financial Officer | 10b5-1 | 9,889 | $192.84 | $1.9M | Form 4 |
| Nov 11, 2026 | Alexis BorisyDirector | 10.6K | – | – | Form 4 | |
| Nov 9, 2026 | Anthony ManciniChief Global Commercialization Officer | 10b5-1 | 810 | $33.62 | $27.2K | Form 4 |
| Nov 9, 2026 | Anthony ManciniChief Global Commercialization Officer | 10b5-1 | 1 | $102.02 | $102 | Form 4 |
| Nov 9, 2026 | Anthony ManciniChief Global Commercialization Officer | 10b5-1 | 811 | $200.00 | $162.2K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 28, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by RVMD's officers and directors from 2020 up to November 19, 2025, 6 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 1 more, back to 2020
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class7.20%
- Farallon Capital Management, L.L.C.with 28 more personsShare of class6.40%
- BlackRock, Inc.Share of class5.70%
- Baker Bros. Advisors LPwith 3 more personsShare of class5.30%
- Vanguard Capital ManagementShare of class5.13%
- JANUS HENDERSON GROUP Ltd.Share of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 7.20% | 15.40M | Nov 5, 20262 filings since Nov 5, 2025 | 13G/A | |
| Farallon Capital Management, L.L.C.with 28 more persons | 6.40% | 13.56M | Aug 13, 20265 filings since May 15, 2025 | 13G/A | |
| BlackRock, Inc. | 5.70% | 12.20M | Jul 29, 20262 filings since Jul 17, 2025 | 13G | |
| Baker Bros. Advisors LPwith 3 more persons | 5.30% | 11.44M | Aug 14, 20263 filings since Aug 14, 2025 | 13G | |
| Vanguard Capital Management | 5.13% | 11.00M | Oct 30, 2026 | 13G | |
| JANUS HENDERSON GROUP Ltd. | 5.10% | 10.74M | Aug 13, 20266 filings since Feb 14, 2025 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Duquesne (Druckenmiller)In the quarter+9.2%
- Citadel Advisors (Griffin)In the quarter+122%
- AQR CapitalIn the quarter+18%
- Point72 (Cohen)In the quarter+253%
- Millennium Mgmt (Englander)In the quarter-62%
- D.E. ShawIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Duquesne (Druckenmiller) | 436.3K | +9.2% | $90M | 2.16% |
| Citadel Advisors (Griffin) | 1.31M | +122% | $269M | 0.15% |
| AQR Capital | 1.53M | +18% | $313M | 0.09% |
| Point72 (Cohen) | 213.0K | +253% | $44M | 0.07% |
| Millennium Mgmt (Englander) | 81.2K | -62% | $17M | 0.01% |
| D.E. Shaw | – | – | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 5.98% of its shares outstanding were held short, +8.5% since the report before.
- Shares held short
- 12.93M
- 5.98%
- Since the report before11.93M on Sep 30, 2026
- +8.5%
- 6.1
- 2.11M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 71%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 14.24M
- Nov 15, 2023: Shares held short 16.25M
- Nov 30, 2023: Shares held short 14.22M
- Dec 15, 2023: Shares held short 14.85M
- Dec 29, 2023: Shares held short 16.19M
- Jan 12, 2024: Shares held short 15.88M
- Jan 31, 2024: Shares held short 16.95M
- Feb 15, 2024: Shares held short 16.96M
- Feb 29, 2024: Shares held short 17.15M
- Mar 15, 2024: Shares held short 16.40M
- Mar 28, 2024: Shares held short 12.00M
- Apr 15, 2024: Shares held short 12.49M
- Apr 30, 2024: Shares held short 12.53M
- May 15, 2024: Shares held short 12.94M
- May 31, 2024: Shares held short 14.81M
- Jun 14, 2024: Shares held short 15.52M
- Jun 28, 2024: Shares held short 16.09M
- Jul 15, 2024: Shares held short 15.76M
- Jul 31, 2024: Shares held short 16.14M
- Aug 15, 2024: Shares held short 16.84M
- Aug 30, 2024: Shares held short 16.51M
- Sep 13, 2024: Shares held short 17.17M
- Sep 30, 2024: Shares held short 16.34M
- Oct 15, 2024: Shares held short 16.66M
- Oct 31, 2024: Shares held short 18.14M
- Nov 15, 2024: Shares held short 16.35M
- Nov 29, 2024: Shares held short 16.16M
- Dec 13, 2024: Shares held short 16.55M
- Dec 31, 2024: Shares held short 16.29M
- Jan 15, 2025: Shares held short 16.59M
- Jan 31, 2025: Shares held short 15.91M
- Feb 14, 2025: Shares held short 14.92M
- Feb 28, 2025: Shares held short 15.84M
- Mar 14, 2025: Shares held short 16.65M
- Mar 31, 2025: Shares held short 16.20M
- Apr 15, 2025: Shares held short 16.43M
- Apr 30, 2025: Shares held short 16.55M
- May 15, 2025: Shares held short 18.88M
- May 30, 2025: Shares held short 18.36M
- Jun 13, 2025: Shares held short 18.16M
- Jun 30, 2025: Shares held short 16.10M
- Jul 15, 2025: Shares held short 13.66M
- Jul 31, 2025: Shares held short 13.93M
- Aug 15, 2025: Shares held short 15.18M
- Aug 29, 2025: Shares held short 16.53M
- Sep 15, 2025: Shares held short 18.05M
- Sep 30, 2025: Shares held short 17.97M
- Oct 15, 2025: Shares held short 19.36M
- Oct 31, 2025: Shares held short 18.02M
- Nov 14, 2025: Shares held short 17.49M
- Nov 28, 2025: Shares held short 16.79M
- Dec 15, 2025: Shares held short 15.07M
- Dec 31, 2025: Shares held short 15.31M
- Jan 15, 2026: Shares held short 14.22M
- Jan 30, 2026: Shares held short 13.07M
- Feb 13, 2026: Shares held short 13.66M
- Feb 27, 2026: Shares held short 14.11M
- Mar 13, 2026: Shares held short 14.46M
- Mar 31, 2026: Shares held short 15.41M
- Apr 15, 2026: Shares held short 13.39M
- Apr 30, 2026: Shares held short 12.80M
- May 15, 2026: Shares held short 11.08M
- May 29, 2026: Shares held short 11.59M
- Jun 15, 2026: Shares held short 12.28M
- Jun 30, 2026: Shares held short 12.88M
- Jul 15, 2026: Shares held short 14.00M
- Jul 31, 2026: Shares held short 11.52M
- Aug 14, 2026: Shares held short 9.72M
- Aug 31, 2026: Shares held short 9.73M
- Sep 15, 2026: Shares held short 9.67M
- Sep 30, 2026: Shares held short 11.93M
- Oct 15, 2026: Shares held short 12.93M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading55.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 55.7% of the shares in the reported trades were short sales, against 58.2% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 55.7%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 58.2%
- Change
- -2.5 pts
- Short sales a dayon average, of 1.36M shares
- 760.2K
- More than atof 3,666 US-listed companies, same days
- 70%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 48.1%
- Oct 14, 2026: Short sales 68.7%
- Oct 15, 2026: Short sales 52%
- Oct 16, 2026: Short sales 52%
- Oct 19, 2026: Short sales 50.7%
- Oct 20, 2026: Short sales 72%
- Oct 21, 2026: Short sales 58.6%
- Oct 22, 2026: Short sales 59.2%
- Oct 23, 2026: Short sales 48.6%
- Oct 26, 2026: Short sales 56.3%
- Oct 27, 2026: Short sales 58.2%
- Oct 28, 2026: Short sales 54.6%
- Oct 29, 2026: Short sales 69.3%
- Oct 30, 2026: Short sales 64.9%
- Nov 2, 2026: Short sales 48.4%
- Nov 3, 2026: Short sales 56.3%
- Nov 4, 2026: Short sales 59.7%
- Nov 5, 2026: Short sales 63.6%
- Nov 6, 2026: Short sales 57.5%
- Nov 9, 2026: Short sales 38.4%
- Nov 10, 2026: Short sales 45.2%
- Nov 11, 2026: Short sales 43.6%
- Nov 12, 2026: Short sales 42.5%
- Nov 13, 2026: Short sales 60.7%
- Nov 16, 2026: Short sales 62.4%
- Nov 17, 2026: Short sales 61%
- Nov 18, 2026: Short sales 56.6%
- Nov 19, 2026: Short sales 66%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Alexis BorisyDirectorDirectly2.33M
- Thilo SchroederDirectorDirectly–
- Mark A GoldsmithSee RemarksDirectly253.3K
- Stephen Michael KelseySee RemarksDirectly286.3K
- Margaret A HornChief Operating OfficerDirectly154.6K
- Jack AndersChief Financial OfficerDirectly119.2K
- Xiaolin WangSee RemarksDirectly116.1K
- Lin WeiChief Medical OfficerDirectly101.4K
- Sandra HorningDirectorDirectly97.8K
- Alan B. SandlerChief Development OfficerDirectly52.6K
- Jeff CisliniSVP & General CounselDirectly51.8K
- Anthony ManciniSee RemarksDirectly39.8K
- Flavia BorelliniDirectorDirectly28.7K
- Sushil PatelDirectorDirectly24.1K
- Barbara WeberDirectorDirectly13.1K
- Frank ClyburnDirectorDirectly10.9K
- Lorence H. KimDirectorDirectly–
- Elizabeth M AndersonDirectorDirectly4,433
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Alexis BorisyDirector | 2.33M | – | Nov 11, 2026 | Form 4 |
| Thilo SchroederDirector | – | 760.9K | Dec 5, 2024 | Form 4 |
| Mark A GoldsmithSee Remarks | 253.3K | 61.8K | Sep 16, 2026 | Form 4 |
| Stephen Michael KelseySee Remarks | 286.3K | – | Nov 16, 2026 | Form 4 |
| Margaret A HornChief Operating Officer | 154.6K | – | Sep 16, 2026 | Form 4 |
| Jack AndersChief Financial Officer | 119.2K | – | Nov 11, 2026 | Form 4 |
| Xiaolin WangSee Remarks | 116.1K | – | Mar 17, 2026 | Form 4 |
| Lin WeiChief Medical Officer | 101.4K | – | Mar 17, 2026 | Form 4 |
| Sandra HorningDirector | 97.8K | – | Jun 18, 2026 | Form 4 |
| Alan B. SandlerChief Development Officer | 52.6K | – | Sep 29, 2026 | Form 4 |
| Jeff CisliniSVP & General Counsel | 51.8K | – | Sep 25, 2026 | Form 4 |
| Anthony ManciniSee Remarks | 39.8K | – | Nov 9, 2026 | Form 4 |
| Flavia BorelliniDirector | 28.7K | – | Nov 13, 2026 | Form 4 |
| Sushil PatelDirector | 24.1K | – | Jun 29, 2026 | Form 4 |
| Barbara WeberDirector | 13.1K | – | Oct 8, 2024 | Form 4 |
| Frank ClyburnDirector | 10.9K | – | Jun 18, 2026 | Form 4 |
| Lorence H. KimDirector | – | 8,945 | Sep 8, 2026 | Form 4 |
| Elizabeth M AndersonDirector | 4,433 | – | Sep 22, 2026 | Form 4 |
A lower bound: it counts only the 18 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund2.78%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.20%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund1.06%
- IWPiShares Russell Mid-Cap Growth ETFWeight in the fund0.98%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.89%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.86%
- SCHMSchwab U.S. Mid-Cap ETFWeight in the fund0.76%
- IYHiShares U.S. Healthcare ETFWeight in the fund0.59%
- VHTVanguard Health Care Index FundWeight in the fund0.46%
- VBVanguard Small-Cap Index FundWeight in the fund0.46%
35 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 324
- Q4 2025: Managers 388
- Q1 2026: Managers 517
- Q2 2026: Managers 691
Institutional investors by quarter
The fund managers holding RVMD, quarter by quarter, from Q1 2020 to Q2 2025, 22 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 691 managers held 214M shares, worth $40.2B. During the quarter 242 opened a position, 68 closed one, 236 added and 149 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+22%
- Farallon Capital ManagementIn the quarter-0.4%
- FMRIn the quarter+44%
- Baker Bros. AdvisorsIn the quarter+20%
- Jupiter TopcoIn the quarter
- Darwin Global ManagementIn the quarter+381%
- Vanguard Capital ManagementIn the quarter+8.7%
- Vanguard Portfolio ManagementIn the quarter+11%
- Nextech InvestIn the quarter
- Paradigm Biocapital AdvisorsIn the quarter-4.4%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 13.70M | +22% | $2.6B |
| Farallon Capital Management | 13.55M | -0.4% | $2.5B |
| FMR | 12.20M | +44% | $2.3B |
| Baker Bros. Advisors | 11.44M | +20% | $2.1B |
| Jupiter Topco | 10.74M | $2.0B | |
| Darwin Global Management | 10.63M | +381% | $2.0B |
| Vanguard Capital Management | 9.09M | +8.7% | $1.7B |
| Vanguard Portfolio Management | 8.29M | +11% | $1.6B |
| Nextech Invest | 7.60M | $1.4B | |
| Paradigm Biocapital Advisors | 6.36M | -4.4% | $1.2B |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Revolution Medicines's filings show?
Who buys and sells is one part of Revolution Medicines's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have RVMD's insiders bought or sold?
From May 28, 2026 to Nov 18, 2026 Revolution Medicines's insiders bought 0 and sold $115M of shares on the market. 99% of the sales were under set 10b5-1 plans.
Which well-known managers hold RVMD?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $313M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.